Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SIDDHARTHA H DEVARAKONDA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1487932398
CMS profile
113148
Location
SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$125,021.17

124 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SIDDHARTHA H DEVARAKONDA

NPI 1487932398 · CMS profile ID 113148

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487932398?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SIDDHARTHA H DEVARAKONDA, NPI 1487932398, CMS profile ID 113148. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487932398?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SIDDHARTHA H DEVARAKONDA, NPI 1487932398, CMS profile ID 113148. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487932398?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SIDDHARTHA H DEVARAKONDA, NPI 1487932398, CMS profile ID 113148, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1487932398?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

124 matching records · $125,021.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 124 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–124 of 124.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $380.0404/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206367369 CMS
AstraZeneca Pharmaceuticals LP $279.7204/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206415685 CMS
AstraZeneca Pharmaceuticals LP $135.0004/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206748931 CMS
AstraZeneca Pharmaceuticals LP $24.1303/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206520732 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,480.0003/28/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223049612 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $740.0003/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223049616 CMS
Janssen Biotech, Inc. $1,110.0003/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175332218 CMS
AstraZeneca Pharmaceuticals LP $1,340.0003/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206734171 CMS
Janssen Biotech, Inc. $1,250.0003/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1175326498 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,480.0003/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223049614 CMS
Janssen Biotech, Inc. $555.0003/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175331329 CMS
Janssen Biotech, Inc. $3,607.5002/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175325874 CMS
AstraZeneca Pharmaceuticals LP $3,350.0002/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206861051 CMS
AstraZeneca Pharmaceuticals LP $70.5202/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1207260483 CMS
Janssen Biotech, Inc. $143.6802/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175326240 CMS
Janssen Biotech, Inc. $6.6102/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175332434 CMS
Janssen Biotech, Inc. $171.1102/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1175332879 CMS
Janssen Biotech, Inc. $4,125.0002/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175330836 CMS
Janssen Biotech, Inc. $167.9401/31/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1175328584 CMS
Janssen Biotech, Inc. $124.9901/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175330330 CMS
Janssen Biotech, Inc. $575.0001/10/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1175331247 CMS
Janssen Biotech, Inc. $825.0001/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1175327669 CMS
AstraZeneca Pharmaceuticals LP $1,340.0001/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206352945 CMS
Janssen Biotech, Inc. $825.0001/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1175327150 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $5,278.75 12
PY2023 $17,523.47 24
PY2024 $67,506.06 62
PY2025 $125,021.17 124

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,238,974.25 131
PY2024 Principal investigator $258,496.46 16
PY2022 Principal investigator $34,879.90 3
PY2021 Principal investigator $41,759.43 5
PY2020 Recipient $1,800.00 2
PY2020 Principal investigator $45,906.75 3
PY2019 Recipient $20,750.00 1
PY2019 Principal investigator $59,030.29 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

131 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $610.92 12/17/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998523
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $239.76 12/17/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998525
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $17.52 12/17/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998527
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,381.48 12/16/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792311
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,171.00 12/15/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792307
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,690.10 12/15/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792309
Principal investigator 1 Janssen Research & Development, LLC $6,191.00 12/15/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430564
Principal investigator 1 PFIZER INC. $544.00 12/11/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228711900
Principal investigator 1 Janssen Research & Development, LLC $12,683.00 12/04/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430433
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,171.32 12/03/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792299
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,171.32 12/03/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792301
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,960.18 12/03/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792303
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $49,945.50 12/03/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792305
Principal investigator 1 Genentech, Inc. $1,816.00 12/01/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211556692
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $40,930.43 11/30/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998513
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $40,930.43 11/30/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998515
Principal investigator 1 PFIZER INC. $3,895.00 11/27/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228711898
Principal investigator 1 Genmab A/S $3,548.00 11/21/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926331
Principal investigator 1 Genmab A/S $4,000.00 11/21/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926335
Principal investigator 1 Genmab A/S $1,500.00 11/21/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926338
Principal investigator 1 Genmab A/S $2,800.00 11/21/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926341
Principal investigator 1 Genmab A/S $1,500.00 11/21/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926345
Principal investigator 1 Genmab A/S $20,000.00 11/21/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926349
Principal investigator 1 Genmab A/S $3,548.00 11/21/2025 Covered Recipient Teaching Hospital
Swedish Medical Center Cherry Hill
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926364
Principal investigator 1 Genmab A/S $4,000.00 11/21/2025 Covered Recipient Teaching Hospital
Swedish Medical Center Cherry Hill
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926368
Principal investigator 1 Genmab A/S $1,500.00 11/21/2025 Covered Recipient Teaching Hospital
Swedish Medical Center Cherry Hill
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926371
Principal investigator 1 Genmab A/S $2,800.00 11/21/2025 Covered Recipient Teaching Hospital
Swedish Medical Center Cherry Hill
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926376
Principal investigator 1 Genmab A/S $1,500.00 11/21/2025 Covered Recipient Teaching Hospital
Swedish Medical Center Cherry Hill
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926380
Principal investigator 1 Genmab A/S $20,000.00 11/21/2025 Covered Recipient Teaching Hospital
Swedish Medical Center Cherry Hill
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926383
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $135.76 11/19/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998517
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $79.92 11/19/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998519
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5.84 11/19/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998521
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,299.00 11/13/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792295
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $837.00 11/13/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792297
Principal investigator 1 Janssen Research & Development, LLC $29,853.00 11/10/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430547
Principal investigator 1 Janssen Research & Development, LLC $4,098.00 10/27/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430587
Principal investigator 1 Amgen Inc. $7,756.00 10/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors No dispute reported 06/30/2026 1246651966
Principal investigator 1 Janssen Research & Development, LLC $8,610.00 10/23/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430877
Principal investigator 1 PFIZER INC. $544.00 10/20/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228711832
Principal investigator 1 PFIZER INC. $408.00 10/20/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228711838
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,762.00 10/17/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792293
Principal investigator 1 AstraZeneca UK Limited $38,800.00 10/15/2025 Non-covered Recipient Entity
SWEDISH HEALTH SERVICES
a phase III,open label,sponsor blind,randomized study of dato dxd with or without osimertinib versus platinum based doublet chemotherapy for participants with egfr mutated locally advanced or metastatic non small cell lung cancer whose disease has progressed on prior osimertinib treatment tropion lung15 No dispute reported 06/30/2026 1185543701
Principal investigator 1 PFIZER INC. $11,306.59 10/14/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228711834
Principal investigator 1 PFIZER INC. $1,335.00 10/14/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228711836
Principal investigator 1 Janssen Research & Development, LLC $12,683.00 10/06/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430489
Principal investigator 1 Janssen Research & Development, LLC $1,238.00 10/06/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430528
Principal investigator 1 Janssen Research & Development, LLC $12,683.00 10/06/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430593
Principal investigator 1 Janssen Research & Development, LLC $4,098.00 10/06/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430646
Principal investigator 1 Janssen Research & Development, LLC $8,585.00 10/06/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430894
Principal investigator 1 Janssen Research & Development, LLC $9,643.00 10/06/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430912
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $61,395.64 09/30/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998499
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,259.00 09/29/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792291
Principal investigator 1 Janssen Research & Development, LLC $10,644.00 09/22/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430771
Principal investigator 1 Janssen Research & Development, LLC $17,170.00 09/05/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430569
Principal investigator 1 Eli Lilly and Company $33,800.00 08/29/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1A/1B STUDY OF THE PAN-KRAS INHIBITOR LY4066434 IN PARTICIPANTS WITH KRAS MUTANT SOLID TUMORS No dispute reported 06/30/2026 1187873769
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $67.88 08/26/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998507
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $19.98 08/26/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998509
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1.46 08/26/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998511
Principal investigator 1 Janssen Research & Development, LLC $8,102.00 08/20/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430710
Principal investigator 1 Genentech, Inc. $289.80 08/05/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211556682
Principal investigator 1 PFIZER INC. $9,299.00 08/04/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228787098
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $101.82 07/28/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998501
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $59.94 07/28/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998503
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4.38 07/28/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998505
Principal investigator 1 Janssen Research & Development, LLC $9,992.00 07/24/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430404
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,514.40 07/02/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185543699
Principal investigator 1 PFIZER INC. $2,019.76 06/30/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228777832
Principal investigator 1 PFIZER INC. $14,419.63 06/30/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228785425
Principal investigator 1 PFIZER INC. $16,548.60 06/30/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228790240
Principal investigator 1 PFIZER INC. $12,891.56 06/30/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228791581
Principal investigator 1 PFIZER INC. $680.00 06/30/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228791889
Principal investigator 1 PFIZER INC. $680.00 06/30/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228792488
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $373.34 06/24/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998491
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $79.92 06/24/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998493
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $182.50 06/24/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998495
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $13.14 06/24/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998497
Principal investigator 1 Janssen Research & Development, LLC $10,500.00 06/23/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430846
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 06/20/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430831
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $58,977.00 06/18/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) No dispute reported 06/30/2026 1236000172
Principal investigator 1 Janssen Research & Development, LLC $4,098.00 06/16/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430428
Principal investigator 1 Janssen Research & Development, LLC $254.00 06/16/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430445
Principal investigator 1 Janssen Research & Development, LLC $608.00 06/16/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430918
Principal investigator 1 Janssen Research & Development, LLC $8,585.00 06/16/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430975
Principal investigator 1 Genentech, Inc. $400.00 06/12/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211556665
Principal investigator 1 PFIZER INC. $47,181.76 06/12/2025 Non-covered Recipient Entity
Swedish Cancer Institute
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228755917
Principal investigator 1 PFIZER INC. $47,181.76 06/11/2025 Non-covered Recipient Entity
Swedish Cancer Institute
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228743599
Principal investigator 1 PFIZER INC. $58,735.00 06/09/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228778566
Principal investigator 1 Janssen Research & Development, LLC $8,585.00 05/30/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430615
Principal investigator 1 Janssen Research & Development, LLC $12,299.00 05/22/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430652
Principal investigator 1 Janssen Research & Development, LLC $10,409.00 04/18/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430799
Principal investigator 1 PFIZER INC. $50,900.00 04/07/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228778717
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $271.52 03/25/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998485
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $159.84 03/25/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998487
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $11.68 03/25/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998489
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $48,856.38 03/25/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) combinations in Adult Participants with Advanced Solid Tumors No dispute reported 06/30/2026 1236000170
Principal investigator 1 Janssen Research & Development, LLC $12,683.00 03/24/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430597
Principal investigator 1 Janssen Research & Development, LLC $4,098.00 03/24/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430756
Principal investigator 1 Janssen Research & Development, LLC $4,098.00 03/24/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430859
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $128,194.87 03/21/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) combinations in Adult Participants with Advanced Solid Tumors No dispute reported 06/30/2026 1236000168
Principal investigator 1 Janssen Research & Development, LLC $10,409.00 03/20/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430484
Principal investigator 1 Janssen Research & Development, LLC $12,294.00 03/10/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430505
Principal investigator 1 Janssen Research & Development, LLC $35,761.00 03/10/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430811
Principal investigator 1 Janssen Research & Development, LLC $4,098.00 03/10/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430999
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,880.00 03/07/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792285
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,294.00 03/07/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792287
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $544.00 03/07/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792289
Principal investigator 1 Janssen Research & Development, LLC $12,683.00 03/07/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430417
Principal investigator 1 Janssen Research & Development, LLC $8,585.00 03/07/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430670
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $33.94 02/25/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998477
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $19.98 02/25/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998479
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $37.44 02/25/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998481
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1.46 02/25/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998483
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $401.81 02/25/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) No dispute reported 06/30/2026 1236000174
Principal investigator 1 PFIZER INC. $47,181.76 02/25/2025 Non-covered Recipient Entity
Swedish Cancer Institute
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228755118
Principal investigator 1 PFIZER INC. $23,590.88 02/25/2025 Non-covered Recipient Entity
Swedish Cancer Institute
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228755556
Principal investigator 1 PFIZER INC. $23,590.88 02/24/2025 Non-covered Recipient Entity
Swedish Cancer Institute
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228756119
Principal investigator 1 PFIZER INC. $47,181.76 02/24/2025 Non-covered Recipient Entity
Swedish Cancer Institute
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228756169
Principal investigator 1 Janssen Research & Development, LLC $12,570.00 02/20/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430369
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $562.00 02/13/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220792283
Principal investigator 1 Genentech, Inc. $289.80 01/28/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211556658
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $34.98 01/27/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998473
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $7.98 01/27/2025 Non-covered Recipient Entity
Swedish Cancer Institute Treatment Center-Swedish First Hill Campus
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998475
Principal investigator 1 Eli Lilly and Company $3,699.77 01/27/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187872589
Principal investigator 1 Janssen Research & Development, LLC $33,006.70 01/23/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430734
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $25,900.00 01/22/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1236000166
Principal investigator 1 PFIZER INC. $47,181.76 01/22/2025 Non-covered Recipient Entity
Swedish Cancer Institute
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228754614
Principal investigator 1 PFIZER INC. $47,181.76 01/21/2025 Non-covered Recipient Entity
Swedish Cancer Institute
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228754934
Principal investigator 1 Janssen Research & Development, LLC $14,877.00 01/20/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175430883
Principal investigator 1 PFIZER INC. $23,590.88 01/09/2025 Non-covered Recipient Entity
Swedish Cancer Institute
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228755553
Principal investigator 1 PFIZER INC. $23,590.88 01/08/2025 Non-covered Recipient Entity
Swedish Cancer Institute
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228754929
Principal investigator 1 Eli Lilly and Company $597,391.20 01/07/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187873895